Theratechnologies Inc T.TH

RE:RE:RE:RE:RE:RE:Melphalen flufenamide

[qwerty22]

You see I don't favour that way of looking at things. The vast majority, almost all, companies will take one drug thru one lead indication. The scatter gun approach to this program is unlikely to lead to THTX running forward on all indication. Let's say they have good data and run on tnbc with th1902. I don't think you suddenly reduce your valuation of the program 5-fold because some indications take a back seat. We are in a super early exploratory phase of the program. The intention here is to define the scope of the program, once those first parameters are laid down I think you can start thinking about markets.
 

Wino115 wrote: What that valuation informs us on is that one PDC for one indication of mylenoma (and 100% of their pipeline is that same drug for various interations of mylenoma) is worth those market caps you've put up there. 

I'm not sure the expected path of earnings from the drug or the peak earnings for it, so don't know what that valuation is supporting as far as a potential revenue number.  It may not be far off from what someone would value the option value of TH1902 at this point, and you'd have to add it in to the other THTX assets for a full market cap.  But it seems clear if TH1902 shows any evidence of being viable, it should be worth more than melflufin given the wider possible usage and revenue opportunity.  Should be multiples of that. 
 

qwerty22 wrote:

 

You saying offerings explain the Sp? It all looks rational to you with that info?

I guess I have the sense that people pick some "over-achievers" like cydy (lol) to compare THTX to. There are perfectly good companies, executing well, who have much more down to earth valuations. I'm all for balance.

So at IPO 2017 had a valuation of 200 mil euros, about 200 mil USD at the time. It was ready to start it's Ph2 at the time. As I said the stock quickly rose in the following 18 months or so (tripled, more if you include one of your offerings). We are one stage behind that at the moment. With this as a comparator it's reasonable for THTX's to be valued sub 200 mil now with good prospects for growth on good data.

I'm not against the idea the whole THTX package is grossly undervalued.

 

scarlet1967 wrote:

 

Since the IPO this company has been diluting their shares just about every year the total proceeds overall were  $455 M!! Balanced view please....

Oncopeptides has completed a directed share issue raising approximately SEK 1,106 million (USD 130 million) Regulatory

March 10, 2021

Oncopeptides has completed a directed share issue raising approximately SEK 1,414 million (USD 144 M)

May 6, 2020 - Regulatory press release

Oncopeptides has completed a directed share issue of approximately SEK 727 million (USD 78 M)

June 28, 2019 - Regulatory press release

Oncopeptides has completed a directed share issue of approximately SEK 546 million

January 24, 2019 - Regulatory press release

Oncopeptides has completed a directed share issue of approximately SEK 314 million

March 22, 2018 - Regulatory press release 38